ADT Duration After Prostate RT for mP... - Advanced Prostate...

Advanced Prostate Cancer

22,372 members28,135 posts

ADT Duration After Prostate RT for mPCa (distant metastases)

6357axbz profile image
14 Replies

The established standard for ADT duration after prostate radiation for non-metastatic, localized high risk PCa is 18 months. My RO has me going on intermittent ADT stopping the ADT 6 months after RT. I have distant oligometaststic (bones) high risk (G8) PCa. I am waiting to receive a response to my question as to how his treatment for my PCa squares with the standard for localized high risk non-metastatic PCa. Opinions from our more knowledgeable members would be appreciated.

Written by
6357axbz profile image
6357axbz
To view profiles and participate in discussions please or .
Read more about...
14 Replies
Tall_Allen profile image
Tall_Allen

So, the 18-month ADT SOC is not for your situation.

You received prostate radiation to debulk the original tumor in the hope of slowing progression. In your bone metastatic situation, the ADT SOC is life-long. It sounds like he is offering intermittent ADT to give you a break from ADT. However, a subset analysis of the Hussain trial suggests that continuous ADT may lead to longer survival than intermittent ADT when there is a low volume of metastases.

6357axbz profile image
6357axbz in reply toTall_Allen

Thanks TA.

Yet, my preference was longer term ADT cause I’ve responded extremely well and don’t feel any major QOL issues. He pushed for IADT. Keep in mind I am in his EXTEND trial (MDA) where I’m considered SOC, which apparently includes debulking via RT post Stampede, while the “extra care” group includes zapping individual oligometaststic mets.

After going on two weeks with no responese to my question I sent a follow-up to respond to my question. If I dont hear back I’ll try to find a way to communicate with a higher authority at MDA.

Break60 profile image
Break60 in reply to6357axbz

Indeed you belong on continuous ADT. That’s why I switched to estradiol patches. See my profile.

6357axbz profile image
6357axbz in reply toBreak60

B60, I’m not sure what your profile tells me. Our cancers and disease histories are way different. Your initial dx was a curable cancer, mine was an aggressive G8 distant metastatic (bones) incurable cancer

Break60 profile image
Break60 in reply to6357axbz

Yes but my initial dx was wrong except for Gleason score of 9 . After RP I was stage 3. I agree it took me awhile to get there compared to you but I got there quickly. Then I was stage 4. But I’ve beaten it back to undetectable with lots of tx. Keep on kicking it’s butt!

6357axbz profile image
6357axbz in reply toTall_Allen

Coincidentally my mo called me moments after I read your responseTA. His position, and I’m paraphrasing, is that there are no relevant presidents for my situation. As you said the phase 3 study was for a curable cancer, not my situation. My ADT included Abitoterone which changes the landscape. He said that for the localized cancer while 18 months may have been equally as effective as 24 or 36 months, 4, 8, 12 or 16 months, for all we know may be equally as effective, that has not been tested.

6357axbz profile image
6357axbz in reply toTall_Allen

And this is what my MO just messaged me:

The study you are on (EXTEND) treats patients with metastatic disease, so XRT + ADT is designed to improve control (with acceptable toxic effects) rather than to cure prostate cancer.

When we control rather than cure cancers, many treatments provide maximal therapeutic benefit or therapeutic ratio after about 6 months of treatments, such as when we give intermittent ADT after surgery or XRT for biochemical progression of disease, or when we give chemotherapy + ADT for patients with more advanced metastatic castration sensitive prostate cancer.

On the EXTEND trial, patients also receive abiraterone in addition to ADT + XRT. If there is synergy between abiraterone + ADT, then the old data using ADT >6 months may become out of date with forthcoming new data in the near future.

Schwah profile image
Schwah

You are saying two things that are very different. You say you have “distant ogliometastic bones” and you say you have “non metastatic PC”. It’s one or the other. Can’t be both. If you are interested ogliometastic, you should add Zytega ASAP and consider SBRT to the mets.

Schwah

6357axbz profile image
6357axbz in reply toSchwah

Please re-read Schwah. I didn’t say I have non-metastatic PC.

Hirsch profile image
Hirsch in reply to6357axbz

In your opening you said your RO is controlling your ADT regimen. Is that really the case or a typo?

6357axbz profile image
6357axbz in reply toHirsch

Not controlling but suggesting to align with his clinical trial. My MO is on board.

RonnyBaby profile image
RonnyBaby

I agree with T_A and the others who see ongoing ADT as the most likely route to go.

Perhaps an ADT holiday might be in order IF you respond well to treatment and the SEs / QOL aren't issues for you.

Here's wishing you the best ....

tallguy2 profile image
tallguy2

Why in the world would you stop ADT when you have confirmed metastatic disease? I'm sorry, fellow traveler; you, and I, will be on ADT for life. Think longer survival times. Read Tall_Allen's post. He's right.

6357axbz profile image
6357axbz in reply totallguy2

Mostly listening to my Drs. There seem to be quite a few here on IADT for many cycles. I have also heard that if you are going to do IADT do it prior to 24 months on for reasonably chance of T recovery.

Not what you're looking for?

You may also like...

Duration of ADT

Just for a quick re cap, diagnosed December 2020. RP January 2021 with Gleason 4+3,...
hg115pb profile image

dilemma ADT duration

apologies first for another longish verbose posting ! I am in a dilemma after my last oncology...
SimMartin profile image

PSA drop after ADT

My PSA went from 14.9 ug/l in May to 5.9 ug/l in June to 0.24 ug/l when tested 2 days ago after...
John347 profile image

Docetaxel vs Surveillance After Radical Radiotherapy for Intermediate- or High-Risk Prostate Cancer

TAKE-HOME MESSAGE •Docetaxel combined with androgen-deprivation therapy (ADT) has improved...
Balsam01 profile image

ADT or Brachytherapy Boost - plus External Beam Radiotherapy for Localized PCa.

New meta-analysis below [1] [2]. I remember a significant study where brachy boost reduced PCa...
pjoshea13 profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.